Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to 285.39%.

  • C4 Therapeutics' EBITDA Margin fell 1306500.0% to 285.39% in Q3 2025 from the same period last year, while for Sep 2025 it was 396.74%, marking a year-over-year decrease of 874300.0%. This contributed to the annual value of 295.46% for FY2024, which is 3235600.0% up from last year.
  • Per C4 Therapeutics' latest filing, its EBITDA Margin stood at 285.39% for Q3 2025, which was down 1306500.0% from 403.73% recorded in Q2 2025.
  • C4 Therapeutics' 5-year EBITDA Margin high stood at 81.07% for Q4 2021, and its period low was 1322.3% during Q2 2023.
  • In the last 5 years, C4 Therapeutics' EBITDA Margin had a median value of 363.8% in 2025 and averaged 512.66%.
  • As far as peak fluctuations go, C4 Therapeutics' EBITDA Margin tumbled by -11772700bps in 2022, and later skyrocketed by 11742400bps in 2024.
  • Over the past 5 years, C4 Therapeutics' EBITDA Margin (Quarter) stood at 81.07% in 2021, then plummeted by -1452bps to 1258.34% in 2022, then increased by 17bps to 1041.92% in 2023, then soared by 35bps to 675.58% in 2024, then soared by 58bps to 285.39% in 2025.
  • Its EBITDA Margin was 285.39% in Q3 2025, compared to 403.73% in Q2 2025 and 363.8% in Q1 2025.